Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:34am, Thursday, 26'th Oct 2023
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
RSV vaccine from GSK shows potential to protect adults 50 to 59
08:42am, Wednesday, 25'th Oct 2023
The results suggest that GSK's shot could help protect a wider population from RSV, which causes thousands of hospitalizations and deaths each year.
RSV Vaccine Shows Hopeful Early Results In 50 To 59-Year-Olds, GSK Says
05:38am, Wednesday, 25'th Oct 2023
GSK said they plan to submit data to regulators as soon as possible and expect a decision in 2024 on whether the shot, already approved for older adults, can be marketed towards people ages 50 to 59.
GSK says latest Arexvy respiratory vaccine trial results ‘positive'
04:32am, Wednesday, 25'th Oct 2023
GSK PLC (LSE:GSK, NYSE:GSK) today unveiled ‘positive' preliminary results from the third phase of its trial of Arexvy, a vaccine against the potentially fatal respiratory syncytial virus (RSV) that�
GSK's RSV vaccine shows positive results in adults aged 50-59
02:25am, Wednesday, 25'th Oct 2023
British drugmaker GSK said on Wednesday its vaccine for respiratory syncytial virus (RSV) showed potential in a late-stage trial to help protect adults aged 50 to 59 years.
GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?
09:01am, Tuesday, 24'th Oct 2023
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
12:47pm, Wednesday, 18'th Oct 2023
Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
GSK cancer immunotherapy receives backing from key EMA committee
04:02am, Monday, 16'th Oct 2023
GSK PLC (LSE:GSK, NYSE:GSK) said its cancer immunotherapy drug, Jemperli (dostarlimab), has been recommended for approval by a key committee at the European Medicines Agency. Specifically, regulators
GSK settlement keeps it on course to remove Zantac overhang by early 2024, analyst says
08:44am, Thursday, 12'th Oct 2023
GSK PLC's (LSE:GSK, NYSE:GSK) latest out-of-court Zantac deal is important to the ongoing "overhang" over the investment case, Citigroup said. The US investment bank reiterated its belief that the F
Why GSK (GSK) Outpaced the Stock Market Today
08:18pm, Wednesday, 11'th Oct 2023
In the most recent trading session, GSK (GSK) closed at $37.56, indicating a +0.59% shift from the previous trading day.
Startup Cerebras stands out in the high-risk AI chip arena: ‘No one has built a chip this big'
07:44pm, Wednesday, 11'th Oct 2023
While most computer-chip makers over the past decades have touted the benefits of an ever-shrinking product, a well-funded Silicon Valley company has built what it says is the largest and fastest-ever
GSK Settles Zantac Cases After Claims Popular Heartburn Drug Causes Cancer
08:30am, Wednesday, 11'th Oct 2023
The pharma giant settled four cases in California for an undisclosed amount to avoid the “distraction” of a trial.
GSK strikes legal settlement over heartburn drug Zantac
02:24am, Wednesday, 11'th Oct 2023
GSK PLC (LSE:GSK, NYSE:GSK) has struck a deal to stop a high profile case concerning its heartburn drug Zantac heading to court in California. The FTSE 100-listed pharma giant said it had reached a co
GSK reaches confidential settlement in California Zantac lawsuit
02:13am, Wednesday, 11'th Oct 2023
GSK on Wednesday said it had reached a confidential settlement on a litigation in California over claims that the British drugmaker's heartburn drug Zantac caused cancer.
GSK (GSK) Surpasses Market Returns: Some Facts Worth Knowing
07:32pm, Monday, 09'th Oct 2023
GSK (GSK) closed at $37.10 in the latest trading session, marking a +1.23% move from the prior day.
